CYP27A1 and neoplasm: Several circulating biomarkers have been recognized as possible indicators for evaluating treatment response, particularly circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and serum markers of bone resorption like tartrate-resistant acid phosphatase 5b (TRACP5b) and the C-terminal telopeptide of type I collagen (CTX).